ClinicalTrials.gg

Program

neracorvir

Also written as “GST-HG141” and “GST-HG141 tablets”.

Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 2 companies.

Furthest: phase 3, since Jul 15, 20256 company-led studies, 3 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fujian Akeylink Biotechnology43 open or runningphase 3since Jul 15, 2025Nov 24, 2022Dec 1, 2026phase 3 · NCT07090759
Fujian Cosunter Pharmaceutical20 open or runningphase 1since May 7, 2020May 7, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2020First study: phase 1 study in Hepatitis BNew to Fujian Cosunter PharmaceuticalFujian Cosunter Pharmaceutical · NCT04386915 · 104 enrolled · China
  2. Apr 23, 2021Phase 1 study in Hepatitis BFujian Cosunter Pharmaceutical · NCT04868981 · 30 enrolled · China
  3. Nov 24, 2022Fujian Akeylink Biotechnology's first study: phase 2 study in Hepatitis B, ChronicNew to Fujian Akeylink BiotechnologyFujian Akeylink Biotechnology · NCT05637541 · 90 enrolled · China
  4. Jul 15, 2025Phase 3 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07090759 · 526 planned · China
  5. Apr 23, 2026Phase 3 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07588009 · 576 planned
  6. Jul 12, 2026Phase 2 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07709520 · 80 planned · China

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07090759
  2. Jan 11, 2028Primary completion: phase 3 study in Hepatitis B, ChronicFujian Akeylink Biotechnology · NCT07588009

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07709520Hepatitis B, Chronic · China2RecruitingFujian Akeylink BiotechnologyOct 1, 202680
NCT07588009Hepatitis B, Chronic3Not yet recruitingFujian Akeylink BiotechnologyJan 11, 2028576
NCT07090759Hepatitis B, Chronic · China3RecruitingFujian Akeylink BiotechnologyDec 1, 2026526
NCT05637541Hepatitis B, Chronic · China2CompletedFujian Akeylink BiotechnologyJul 24, 202490
NCT04868981Hepatitis B · China1CompletedFujian Cosunter PharmaceuticalFeb 23, 202230
NCT04386915Hepatitis B · China1UNKNOWNFujian Cosunter PharmaceuticalMay 30, 2021104

How it is read

Names in the registry

  • “GST-HG141”, 4 entries
  • “GST-HG141 tablets”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.